Prothena (NASDAQ:PRTA) Hits New 12-Month Low at $21.31

Prothena Co. plc (NASDAQ:PRTA)’s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $21.31 and last traded at $21.96, with a volume of 17476 shares trading hands. The stock had previously closed at $21.99.

Analysts Set New Price Targets

Several equities research analysts recently commented on PRTA shares. StockNews.com lowered Prothena from a “hold” rating to a “sell” rating in a research report on Monday, February 19th. Oppenheimer dropped their price target on Prothena from $98.00 to $80.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 20th. Royal Bank of Canada dropped their price target on Prothena from $36.00 to $35.00 and set a “sector perform” rating on the stock in a research note on Friday, February 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research note on Wednesday, April 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Prothena in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $69.63.

Prothena Stock Down 1.6 %

The stock has a market capitalization of $1.13 billion, a PE ratio of -7.50 and a beta of 0.21. The firm has a 50 day moving average price of $26.22 and a 200 day moving average price of $33.12.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.03). The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $2.15 million. Prothena had a negative return on equity of 24.84% and a negative net margin of 160.91%. The business’s revenue for the quarter was down 99.4% compared to the same quarter last year. During the same period last year, the company earned $0.12 earnings per share. On average, equities analysts forecast that Prothena Co. plc will post -4.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Karin L. Walker sold 5,000 shares of Prothena stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $34.00, for a total transaction of $170,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 28.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Prothena

A number of hedge funds have recently bought and sold shares of PRTA. Wellington Management Group LLP lifted its holdings in Prothena by 21.1% during the fourth quarter. Wellington Management Group LLP now owns 2,594,102 shares of the biotechnology company’s stock worth $94,270,000 after acquiring an additional 452,455 shares during the period. Bank of America Corp DE lifted its holdings in Prothena by 363.9% during the first quarter. Bank of America Corp DE now owns 564,441 shares of the biotechnology company’s stock worth $27,358,000 after acquiring an additional 442,770 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Prothena by 10.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,237,351 shares of the biotechnology company’s stock worth $153,986,000 after acquiring an additional 417,338 shares during the period. State Street Corp lifted its holdings in Prothena by 20.0% during the first quarter. State Street Corp now owns 2,367,583 shares of the biotechnology company’s stock worth $86,583,000 after acquiring an additional 394,633 shares during the period. Finally, Armistice Capital LLC bought a new stake in Prothena during the fourth quarter worth $10,103,000. 97.08% of the stock is currently owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.